Drug Trial Radar · NCT03484702
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
Last checked: Nov 19, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
113
Actual
Start
Jun 5, 2018
Primary completion
Dec 15, 2023
Study completion Dec 15, 2023
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Apr 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of JCAR017 in participants with aggressive B-cell non-Hodgkin lymphoma (B-NHL)
Conditions
- Lymphoma, Non-Hodgkin
Interventions
JCAR017Drug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR) Per Independent Review Committee in Cohorts 1, 2 and 3Time frame: From JCAR017 infusion until disease progression, end of study, the start of another anticancer therapy, or hemopoietic stem cell transplant (HSCT) (up to approximately 63 months)
- Overall Response Rate (ORR) Per Investigator in Cohort 4Time frame: From JCAR017 infusion until disease progression, end of study, the start of another anticancer therapy, or hemopoietic stem cell transplant (HSCT) (up to approximately 63 months)
- Overall Response Rate (ORR) Per Investigator in Cohort 5Time frame: From JCAR017 infusion until disease progression, end of study, the start of another anticancer therapy, or hemopoietic stem cell transplant (HSCT) (up to approximately 63 months)
- Number of Participants With Adverse Events in Cohort 7Time frame: From leukapheresis to end of study (up to approximately 63 months)
- Number of Participants With Serious Adverse Events (SAEs) in Cohort 7Time frame: From leukapheresis to end of study (up to approximately 63 months)
- Number of Participants With Increase From Baseline in Select Hematology Parameters - Cohort 7Time frame: At Baseline and Day 29 after JCAR017 infusion
- Number of Participants With Increase From Baseline in Select Serum Chemistry Parameters - Cohort 7Time frame: At Baseline and Day 29 after JCAR017 infusion
Locations
20 sites in 11 countries. Site status is shown where the registry gives one.
Local Institution - 101
Vienna, Austria
Local Institution - 351
Ghent, Belgium
Local Institution - 551
Helsinki, Finland
Local Institution - 202
Lille, France
Local Institution - 203
Paris, France
Local Institution - 201
Pierre-Bénite, France
Local Institution - 151
Cologne, Germany
Local Institution - 152
Dresden, Germany
Local Institution - 155
Heidelberg, Germany
Local Institution - 154
München, Germany
Local Institution - 153
Ulm, Germany
Local Institution - 402
Milan, Italy
Local Institution - 401
Torino, Italy
Local Institution - 601
Chuo-ku, Tokyo, Japan
Local Institution - 602
Minato-ku, Tokyo, Japan
Local Institution - 301
Rotterdam, Netherlands
Local Institution - 451
Barcelona, Spain
Local Institution - 251
Bern, Switzerland
Local Institution - 501
London, United Kingdom
Local Institution - 502
Manchester, Lancashire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.